Our Story
A world-class team of clinicians, scientists, and engineers advancing the future of neonatal brain monitoring through AI-powered medical technology.
NeuroBell is an Irish medtech company developing AI-powered neonatal brain monitoring technology to improve outcomes for the world’s most vulnerable patients. Founded as a spinout from University College Cork and the internationally recognised INFANT Research Centre, NeuroBell combines patent-pending technology, deep learning AI, and clinically annotated EEG datasets to make advanced neonatal brain monitoring more accessible worldwide. Founded by Dr. Mark O’Sullivan, Dr. Alison O’Shea, and Colm Murphy, the company secured €2.1 million in seed funding in 2023 from leading healthcare and technology investors. NeuroBell is an ISO 13485-certified medical device manufacturer, and its first product, NeuroBell Luna, is currently undergoing clinical validation ahead of regulatory submission.
Our achievements timeline
Research Begins
Pioneering research begins, establishing the scientific foundation behind the product.
2015
Research & Development
Enterprise Ireland Comm. Fund awarded to commercialise clinical & engineering research from at the INFANT Centre, University College Cork.
2021 - 2022
Spinout & seed funding
NeuroBell spins out of UCC and secures €2.1m in funding to expand team & bring product to market.
2023
Design freeze & clinical validation
Development and clinical validation of NeuroBell Luna with partners across EU & US, including CUH, Parkview Health & Texas Children's Hospital.
2024 - 2025
FDA clearance & product launch
FDA clearance and US market launch for Luna is anticipated in 2026.
2026
Ready to bring
continuous EEG to your NICU ?
Contact our team to learn more